Physician profile
German A Oliver
NPI 1518066372
$1,183.27
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $169 · 2021: $404 · 2022: $257 · 2023: $215 · 2024: $13.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $228.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $606.36 | 2020-2024 | |
| Pfizer INC. | $119.16 | 2019-2023 | |
| Ironwood Pharmaceuticals, INC | $75.87 | 2020-2021 | |
| Daiichi Sankyo INC. | $53.63 | 2022-2023 | Injectafer |
| Celgene Corporation | $50.42 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $49.81 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $41.95 | 2021-2022 | |
| Redhill Biopharma INC. | $41.04 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Takeda Pharmaceuticals U.S.A., INC. | $23.22 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.30 | 2021 | |
| Ardelyx, INC. | $18.81 | 2022 | |
| Shionogi INC | $18.81 | 2019 | |
| Endo Pharmaceuticals INC. | $17.44 | 2019 | |
| Nestle Healthcare Nutrition INC. | $15.43 | 2021 | |
| Alfasigma USA, INC. | $15.32 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $13.70 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw German Oliver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.